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1. Introduction 
1.1 History 
Tumors of the superior sulcus represent less than 5% of lung malignancies. The distinctive 
symptomatology was first described by Edwin Hare in 1838 [1], and it has been nearly 80 
years since clinical and radiographic features of this tumor were described by Dr Henry 
Pancoast, a radiologist, in 1924 [2]. As a radiologist, he noted the difficulty in detecting the 
tumor on a plain chest radiograph. He initially thought that these tumors arose from 
epithelial crest cells from the fifth brachial cleft. These tumors have been named Pancoast 
tumors or Pancoast-Tobias tumors after further descriptions of their features by these 
authors in 1932 [3, 4].  This was the first time that bronchogenic carcinoma was recognised 
as the primary cause of this syndrome.  
Prior to the 1950s, superior sulcus tumors were uniformly fatal. Chardack and McCallum 
reported a long-term survival after surgical resection and postoperative irradiation therapy 
[5]. Paulson, using preoperative irradiation followed by surgical resection, published the 
first series, which included 18 patients, in 1966 [6]. Shaw and Paulson identified that 
preoperative irradiation and a well-defined resection were associated with a 5-year survival 
of 34% [7]. Based upon these studies, preoperative irradiation and an extended 
posterolateral paravertebral thoracotomy (Shaw Paulson approach) has been the “standard 
of care” over the last 5 decades. However   surgical resection remained limited to tumors 
invading the ribs only, and any further involvement of vascular or neural structures was 
still considered to remain a contraindication for an operation. This was changed by 
Dartevelle who was the first to develop an anterior transcervical approach for the resection 
of tumors involving subclavian vessels. Later on several other modifications of this 
technique were reported but with no remarkable improvement on overall survival. 
In the last century, the management of the superior sulcus tumor changed from 
inoperability and incurability to the current regimen of preoperative chemoradiation 
therapy, with an attempt at complete resection. Interest in trimodality treatment led to the 
South-West Oncology Group (SWOG) 8805 study of induction chemoradiotherapy 
(cisplatin, etoposide, 45Gy) followed by surgery that resulted in a complete response rate of 
22% and encouraging results [8]. A recent prospective phase II study (SWOG 9416) suggests 
that preoperative concurrent chemoradiation (cisplatin, etoposide, 45Gy) improves the rate 
of complete resection, intermediate survival and decreases the rate of local or distal 
recurrence [9]. The 2-year survival was 55% for all eligible patients and 70% for patients who 
had a complete resection.  
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The superior sulcus tumor is a rare tumor posing a unique challenge to thoracic surgeons. 
The current regimen of preoperative chemoradiation with complete surgical resection leads 
to reasonable long term survival. Progress is being made in the understanding of the 
anatomy and biology of this disease. A choice of incisions provides options that have the 
potential to increase the rate of complete resection. New techniques allow resection of 
structures that were previously considered unresectable. Future efforts to improve the 
results will entail not only multidisciplinary approach to en bloc extended resection of 
adjacent structures but also preoperative therapy (chemotherapy or biologic agents) that 
yields greater tumor regression, thereby improving complete resection rates  that are so 
critical to long-term survival in this form of non-small cell lung cancer (NSCLC).      
2. Definition and surgical anatomy 
Pancoast tumor is a cancer of the apex of the lung with no intervening lung tissue between 
tumor and chest wall. Subsequently, there is involvement of structures of the apical chest 
wall above the level of the second rib. The chest wall involvement may be limited to 
invasion of parietal pleura or may extend deeper to involve the periosteum or the bone of 
the first rib or apical vertebral bodies, or it may include invasion of subclavian vessels, the 
nerve roots of the brachial plexus or the stellate ganglion. Involvement of the chest wall only 
at the level of the second rib or lower should not be considered to meet the criteria for 
Pancoast tumor [10]. An apical tumor involving only the visceral pleura and not the chest 
wall by clinical staging should not be classified as a Pancoast tumor. However, it seems 
reasonable to include tumors that are thought to involve chest wall by clinical criteria.  
Superior sulcus tumors may occur in the three compartments of the thoracic inlet and 
symptoms are related to the location. The anterior compartment lies anterior to the insertion 
of the anterior scalene muscle onto the first rib, the middle compartment extends from there 
to the posterior border of the middle scalene muscle, whereas the posterior compartment 
lies behind the middle scalene muscle [11]. Tumors located in the anterior component may 
invade the subclavian vessels, whereas those in the middle mainly invade the brachial 
plexus (Figures 1, 2). Posterior Pancoast tumors usually invade the stellate ganglion or 
vertebral bodies (Figure 3). 
 
 
Fig. 1. Pancoast tumor located in the anterior component (anterior Pancoast tumor). 
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Fig. 2. Pancoast tumor occupying the middle component (median Pancoast tumor). 
 
 
Fig. 3. Pancoast tumor located in the posterior component (posterior Pancoast tumor). 
In case of invasion of the brachial plexus, patients often present with intense pain that 
begins in the shoulder and scapular region and extends down to the ulnar aspect of the arm 
(T1 dermatome) onto the small and ring fingers (C8 dermatome). Due to increasing pressure 
on the nerve roots, muscle atrophy of the ulnar aspect of the hand and loss of the triceps 
reflux can occur. In about 20-30% of patients, tumor invasion of the sympathetic chain and 
the stellate ganglion causes Horner’s syndrome (ipsilateral ptosis, miosis and anhydrosis) 
[12].  
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COMPARTMENT BOUNDARIES included STRUCTURES 
SIGNS AND 
SYMPTOMS 
Anterior  
Between 
sternum and 
anterior edge 
of anterior 
scalene muscle. 
Platysma, 
sternocleidomastoid and 
omohyoid muscles, jugular 
and subclavian veins, 
scalene fat pad. 
Pain radiating to 
the upper anterior 
chest wall, venous 
thrombosis. 
Middle  
Between 
anterior and 
posterior 
border of 
middle scalene 
muscle 
Anterior and middle 
scalene muscles, subclavian 
artery and primary 
branches, phrenic nerve, 
trunks of brachial plexus 
Pain and 
parasthesia 
radiating to the 
shoulder and 
upper limb, 
arterial 
thrombosis, 
diaphragmatic 
paralysis 
Posterior  
Behind middle 
scalene muscle  
Posterior scalene muscle, 
posterior scapular artery, 
posterior aspect of 
subclavian and vertebral 
artery, paravertebral 
sympathetic chain, stellate 
ganglion, nerve roots of 
brachial plexus, long 
thoracic and spinal 
accessory nerves, neural 
foramina, vertebral bodies 
and prevertebral muscles. 
Pain in the axilla 
and in the medial 
part of the upper 
arm, Horner’s 
syndrome. 
Table 1. Anatomical definition of the thoracic inlet and main clinical features in case of 
superior sulcus tumor invasion [13].  
3. Biological behaviour 
Advanced molecular biology techniques have accelerated the understanding of cancer 
biology. It is well established that the application of such technology has led to the 
recognition of lung cancer as a molecularly diverse set of tumor types whose only 
commonality is their origination in the lung [14]. Lung cancer classification is far more 
complex than the simplistic grouping into small cell and non-small cell variants with a 
comparable outcome when treated in a similar fashion [15]. Histologic subdivision of lung 
cancer uses only one of many phenotypic manifestations of the genetic changes that 
underlie lung cancer development. 
Lung cancer development is a result of a stepwise progression of malignant transformation 
of normal respiratory epithelium. This transformation is driven by the cumulative effect of 
genetic alterations induced predominantly by inhaled carcinogens from tobacco smoke [16]. 
The Noguchi classification of lung adenocarcinoma is a pioneering effort to relate tumor 
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histology with clinical and radiologic characteristics. This has resulted in the identification 
of atypical adenomatous hyperplasia and adenocarcinoma in situ as preinvasive neoplastic 
lung lesions that serve as precursors to invasive lung adenocarcinoma through a progressive 
transformation into the type A, B, and C adenocarcinomas with lepidic growth (referring to 
growth along alveolar structures) characterized by an increasing component of invasive 
carcinoma but showing excellent survival outcome, and the type D, E, and F solid-type 
adenocarcinomas with a well-recognized poor prognosis [17]. The most frequently 
described acquired genetic aberrations within the tumor involve the tumor protein p53 
(TP53), KRAS, fragile histidine triad (FHIT), epidermal growth factor receptor (EGFR), 
cyclin-dependent kinase 2a (CDKN2), LKB1, retinoblastoma (RB), and Myc genes. Larger 
genomic mishaps such as chromosomal deletions involving the short arms of chromosomes 
1, 3, and 9 (del 1p36, del 3p, and del 9p, respectively) are also frequently observed in 
different lung cancer histologic subtypes and stages. More recently, inversion translocation 
of the echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma 
kinase (ALK) genes on chromosome 2 (2p21 and 2p23) was shown to characterize a small 
subset of NSCLC with a characteristic clinical and histologic profile. The discovery of other 
molecularly defined lung cancer subsets is likely to be hastened by this finding [18]. 
The treatment options for patients with lung cancer have improved considerably in recent 
years. Improvements in survival have been noted for patients with every stage of the disease 
with the integration of new systemic therapy options, improvements to local therapy, and 
supportive care measures. A number of molecularly targeted agents that modulate a wide 
array of cell signaling pathways are currently under development. The remarkable success 
achieved with the use of EGFR tyrosine kinase inhibitors and the ALK inhibitors are the 
initial steps toward an era of individualized treatment options for patients with NSCLC. 
Several groups are now involved in screening tumor specimens for dominant oncogenic 
drivers in individual patients to guide treatment selection. A total of 13 known molecular 
abnormalities including 8 mutations are evaluated in the tumor specimens. By developing 
novel clinical trials across institutions to target each of these molecular events, the oncologist 
is evaluating a variety of individualized treatment approaches for patients with NSCLC. 
Because these molecular changes are noted in much smaller subsets of patients, such clinical 
trials are unlikely to complete accrual within a single institution in a reasonable time and 
therefore require such collaborative efforts to accelerate research. 
The tremendous increase in the knowledge of lung cancer biology notwithstanding, a 
number of important questions remain unanswered. With lung cancer in never-smokers 
having been recognized as a unique entity, insights into the underlying mechanism and 
etiological factors will help in the development of novel therapies for this group of patients. 
The differences in lung cancer biology based on gender are another important area of 
research that will hopefully lead to the development of gender-driven therapeutic 
approaches. As newer therapeutic options are developed, participation of patients in clinical 
trials must be encouraged and supported by health care delivery systems. Currently, fewer 
than 5% of the patients diagnosed with cancer participate in therapeutic clinical trials [19] 
Concerning Pancoast tumors it was traditionally believed that the biology  was different 
from that of other non–small cell lung cancers and in that these tumors had a strong 
propensity to local invasion and a diminished incidence of spread through lymphatic or 
hematogenous routes. However, recent data does not support this belief [20]. Additionally 
the incidence of pathologic N2 disease, is similar to that of other peripheral stage I or II lung 
tumors and survival is better following a formal lobectomy rather than a wedge resection 
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alone. The unique feature of Pancoast tumors appears not to lie in the tumor biology but 
rather in the anatomy of the region in which these tumors occur.   
Ipsilateral supraclavicular nodal involvement is classified as N3 disease. However, there is 
some evidence that such involvement in patients with a Pancoast tumor may not preclude 
long-term survival. Ipsilateral supraclavicular node involvement in these patients may have 
a prognostic importance more akin to that of N1 disease [21].   
4. Surgical approaches 
4.1 Posterior approach 
The ideal tumor for the posterolateral approach is situated posteriorly in the superior sulcus 
and does not invade the anterior structures of the thoracic inlet. It may however invade the 
vertebral bodies or the brachial plexus. The C8 and T1 nerve roots are most commonly 
invaded. It is important to assess the patient’s neurologic function preoperatively and to 
inform him properly concerning postoperative neurological morbidity [22]. 
The patient is placed in the lateral decubitus position.  The incision starts anteriorly, 
allowing exploration of the chest cavity (usually through the fourth/fifth interspace) to 
assess resectability. The extension of the tumor onto the thoracic chest wall, thoracic inlet, 
lung, and mediastinum should be assessed. The incision is then extended posteriorly around 
the tip of the scapula and vertically upward between the spinous processes and posterior 
edge of the scapula, up to C7 (Figure 4). The division of muscle layers starts from the 
latissimus dorsi and trapezius to expose and subsequently divide the serratus anterior, 
rhomboidius major and minor, and levator scapulae muscles. The dorsal scapular nerve and 
scapular artery branches should be avoided when dividing the rhomboids at their insertion 
into the medial border of the scapula. These muscles will all be meticulously 
reapproximated at the end of the case. The chest wall resection is carried out first, in order to 
release the involved chest wall into the pleural cavity allowing for a safer lobectomy. En 
bloc resection of the chest wall and lung is preferred to extrapleural dissection without rib 
sacrifice, which often leads to incomplete resection. In most cases, the first two or three ribs 
are removed, although more ribs may be resected if required. The resection should 
guarantee large free margins, resecting 3-4 cm of uninvolved rib anteriorly and one rib and 
the intercostal muscle below the tumor inferiorly.  
 
 
Fig. 4. Posterior approach for Pancoast tumors (Shaw Paulson thoracotomy). The incision 
extends  up to the 7th cervical vertebrae.  
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First, the anterior and inferior dissection is started along the established resection margins 
beginning with the healthy rib. The invaded ribs and intercostal muscles are divided using 
rib shears and electrocautery, in succession from below to above, and the intercostal 
neurovascular pedicles are ligated. When the first rib is reached, the anterior and middle 
scalenus insertions to the second and first rib are divided with cautery, exposing the 
structures of the thoracic inlet crossing above the first rib. It is very important to note the 
insertions of the anterior and middle scalene on the first rib. Also of note is the phrenic 
nerve lying on the anterior surface of the anterior scalene. This, as well as the subclavian 
vein and artery should be identified before dividing the anterior scalene. 
The posterior phase of the dissection starts by incising the erector spinae muscle along its 
anterior border from T1 to T5 and retracting it outward to expose the costotransverse joint. If 
the tumor involves the parietal pleura only, with no rib or vertebral erosion, the ribs may be 
disarticulated from the transverse processes, preserving the latter structures. The intercostal 
nerve and vessel originating from the intervertebral foramen are identified and divided 
between clips or sutured with 3-0 Prolene. This manoeuvre is repeated for each rib, until the 
first rib is reached. If the tumor involves the ribs posteriorly, the transverse processes are 
removed along with the adjacent lateral cortex of the vertebrae using an osteotome. 
The lower trunk of the brachial plexus is identified by retracting the first rib downward and 
can be dissected posteriorly until it splits into the C8 (above the neck of the first rib) and T1 
(below the neck of the first rib) nerve roots. Most commonly, the neoplastic invasion is 
limited to the first thoracic nerve root, which may be divided medial to its entry into the 
lower trunk and lateral to tumor involvement, keeping the C8 nerve root intact. This is very 
important in order to avoid the morbidity of loss of function of the intrinsic muscles of the 
hand [23]. When the tumor involves the C8 nerve, the lower trunk of the brachial plexus 
should be divided medially, at its origin from the spine. When the T1 nerve root is divided 
there is usually only a sensory deficit along the medial aspect of the hand.  
With a hand inside the chest, the first rib is cut either at its neck if the head is not involved 
with tumor or beyond the attachment of its tubercle to the transverse process. The chest wall 
is then released from the apex of the chest en bloc by sequentially dividing the lower portion 
of the stellate ganglion and first intercostal artery.  
Then a formal upper lobectomy with systematic lymph node dissection is the final step. The 
tumor attached to the chest wall is removed as one specimen. At this time a routine 
evaluation of the margins is done, obtaining biopsies and placing clips for helping 
postoperative irradiation.  
It is not usually necessary to reconstitute the posterior defect in the chest wall, as it is 
covered by the scapula. A defect of three or more ribs or over the tip of the scapula should 
be closed with synthetic mesh. It is well established that meticulous reapproximation and 
closure with mesh prevents major morbidity in respiratory chest wall motion. 
The posterior approach allows excellent exposure of the posterior chest wall including the 
transverse processes and thoracic nerve roots. It also allows standard exposure of the 
pulmonary hilum. However, surgical manipulation of the subclavian vessels is very 
difficult. Furthermore, visualization of the apex is poor making assessment of the 
appropriate extent of resection problematic. 
4.2 Anterior approach 
The anterior surgical approach to Pancoast tumors is modified to optimize exposure. 
Depending on location and size of the tumor there are two basic incisions: 1) a 
transclavicular incision and 2) a hemi-clamshell incision with supraclavicular extension. 
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The transclavicular incision (Dartevelle approach) is used with the patient in the supine 
position with the neck hyperextended and the head turned toward the uninvolved side [24]. 
The skin is prepared from the mastoid process to the xyphoid process and from the 
midaxillary line to the contralateral midclavicular line. The cervicotomy uses an L-shaped 
incision that follows the anterior border of sternocleidomastoid muscle and the inferior 
border of the clavicle to the deltopectoral groove (Figure 5). In first reports, a standard 
clavicular resection was included but this was associated with functional disability and 
suboptimal cosmetic results. An alternative approach involves bisecting the manubrium to 
preserve the claviculomanubrial junction (Grunenwald approach) (Figure 6) [25].   
 
 
Fig. 5. Anterior transclavicular approach for Pancoast tumors (Dartevelle approach). 
 
 
Fig. 6. Anterior approach for Pancoast tumors (Grunenwald approach). 
The hemi-clamshell incision is a clavicular-sparing approach [23]. The patient is in full 
lateral position with slight posterior rotation. The skin is prepared in the same manner as 
described for the transclavicular approach. In patients requiring a supraclavicular extension, 
the ipsilateral arm is incorporated in the skin preparation.    
The sternocleidomastoid muscle is divided and the medial half of the clavicle is resected. 
Variations of this approach include simple division of the mid-portion of the clavicle and 
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subsequent reconstruction with plates and screws, or disarticulation of the sternoclavicular 
joint and lateral retraction of the clavicle. 
The sequential steps involve dissection of the jugular veins, dissection of the arteries and 
exposure of the brachial plexus. Dissection of the jugular veins is important for adequate 
exposure. Ligation of the internal jugular vein is well tolerated. Especially on the left side, 
the thoracic duct is ligated with care.  
The anterior scalene muscle is divided either at its insertion on the scalene tubercle of the 
first rib, or as close as it gets to its origin at the transverse processes of C3-C5. The anterior 
scalene muscle is well defined in 2/3 of patients and may be located behind the subclavian 
artery or split into two with the artery passing between the bundles [26].   The subclavian 
artery is mobilized by dividing most of its branches. Care is taken to preserve the vertebral 
artery and resection of the vessel is done only if it is involved with the tumor. A 
preoperative Doppler ultrasound is important to detect any extracranial occlusive disease. If 
the subclavian artery is invaded by the tumor, the affected portion is resected and 
reconstructed with a PTFE vascular graft. A small dose of heparin is administered during 
vascular clamping. Following anterior traction of the subclavian artery, the middle scalene 
muscle comes into good view.  
The middle scalene muscle originates from the transverse processes of C2-C7and inserts 
onto the first rib between the subclavian groove and the posterior tubercle of the transverse 
process. In tumors invading the middle compartment of the thoracic inlet, the middle 
scalene muscle may be extensively involved. In these cases resection of the middle scalene 
muscle requires mobilization along its origin from the lower cervical vertebrae.  
At this stage the cords of the brachial plexus are identified laterally. The anterior surface of 
vertebral bodies C7 and T1 are in view. The sympathetic chain and the stellate ganglion are 
lying in front of the vertebral bodies of C7 and T1. C8 and T1 nerve roots are visualized and 
dissected medially up to the lower trunk of the brachial plexus. The C8 nerve component of 
the plexus is preserved for better functional outcome of the upper limb. For carcinomas 
affecting the spine a multilevel unilateral laminectomy, nerve root division inside the spinal 
canal and vertebral body division can be performed by neurosurgeons. 
The chest wall resection is performed with progressive resection of the first, second and 
third ribs. The ribs are resected from the costochondral junction anteriorly to the articulation 
with the transverse process.  To facilitate mobility of the en bloc mass, resection of a short 
segment of rib (1-2 cm), may create a “mobile” chest wall. Resection of lower ribs is difficult 
and pulmonary resection by means of a conventional lobectomy is difficult. It may 
sometimes be necessary to perform a separate posterior thoracotomy to complete the 
resection and lymph node dissection.  
The anterior approach facilitates direct visualization of vascular structures and provides 
excellent exposure of brachial plexus, sympathetic chain and stellate ganglion. There is 
freedom for hemi-vertebrectomy for tumors invading anterior parts of the vertebrae. 
Oncological clearance seems to be optimal due to the fact that the tumor is the last structure 
to be encountered. Finally the anterior approach seems to offer less morbidity than the 
posterior one. 
A relative disadvantage of the anterior approach is the difficulty in removing the 
transverse processes and the head of the ribs in order to disarticulate them. The need to 
perform an additional posterior thoracotomy for the lobectomy and systematic 
mediastinal lymph node dissection could be seen as a factor that negates the routine use 
of anterior approach. 
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4.3 Future perspectives 
Although the understanding of the biology and treatment of Pancoast tumors has evolved 
significantly, it is clear that more progress is needed. When considering that a large 
randomized trial may not be performed due to the relative rarity of the disease, the 
present clinical evidence from several phase II studies suggests that  induction 
chemoradiotherapy and surgery be recommended as modern standard of care for 
Pancoast tumors. However, there are many issues still remaining for debate or are under 
discussion [27]. 
1. Recruitment of patients with N2 disease for surgery. 
2. Ipsilateral supraclavicular lymph node disease should be considered as N1 disease. 
3. The role of high dose preoperative radiotherapy (6000 cGy). 
4. The role of prophylactic cranial irradiation. 
5. The role of adjuvant postoperative chemotherapy. 
6. The role of more aggressive surgery in cases of extensive involvement of the brachial 
plexus.  
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